Why must the insulin infusion be continued even when blood glucose becomes low in hyperosmolar hyperglycemic state (HHS) and diabetic ketoacidosis (DKA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Why Insulin Infusion Must Continue Despite Low Blood Glucose in DKA and HHS

Insulin infusion must be continued even when blood glucose becomes low in DKA and HHS because the primary goal is to resolve the underlying metabolic crisis—clearing ketones in DKA and correcting hyperosmolality in HHS—not simply lowering glucose. 1

The Core Pathophysiology

The fundamental problem in both DKA and HHS extends beyond hyperglycemia. In DKA, insulin deficiency triggers uncontrolled lipolysis and ketogenesis, producing life-threatening ketoacidosis 2. In HHS, severe hyperosmolality develops from profound dehydration and hyperglycemia 2. Stopping insulin prematurely—even when glucose normalizes—allows these dangerous metabolic processes to resume.

Why Glucose Drops Faster Than the Crisis Resolves

Blood glucose responds rapidly to insulin and fluid resuscitation, typically falling at 50-75 mg/dL per hour 3. However, the resolution of ketoacidosis (achieving bicarbonate >15 mEq/L, pH >7.3, anion gap <12) and correction of hyperosmolality (osmolality <315 mOsm/kg) take substantially longer 1. This creates a critical window where glucose may reach 150-250 mg/dL while the patient remains in metabolic crisis.

The Management Algorithm When Glucose Becomes Low

For DKA:

  • When glucose falls to 200 mg/dL: Add dextrose-containing IV fluids (D5W or D10W) alongside continued 0.9% saline 1
  • Maintain glucose between 150-200 mg/dL until ketoacidosis resolves 1
  • Continue insulin infusion at the same or reduced rate (consider decreasing from 0.1 to 0.05 units/kg/h if glucose <140 mg/dL) 3
  • Do not stop insulin until: bicarbonate >15 mEq/L, pH >7.3, anion gap normalized, and patient able to eat 1

For HHS:

  • When glucose falls to 250 mg/dL: Add dextrose-containing fluids 1
  • Target glucose 200-250 mg/dL until hyperosmolality resolves 1
  • Continue insulin until calculated osmolality falls to <315 mOsm/kg 1

Critical Pitfalls to Avoid

The most dangerous error is premature discontinuation of IV insulin 4. This leads to:

  • Rebound ketoacidosis in DKA patients, requiring readmission 5, 4
  • Recurrent hyperosmolality in HHS 4
  • Increased mortality and morbidity 4

The Transition Protocol

When the metabolic crisis has resolved AND the patient can eat:

  1. Give subcutaneous basal insulin 2-4 hours before stopping IV insulin 5, 1
  2. Continue IV insulin during this overlap period to prevent metabolic relapse 5, 1
  3. Recent evidence suggests adding low-dose basal insulin analog during the IV infusion may prevent rebound hyperglycemia without increasing hypoglycemia risk 5

Additional Monitoring Considerations

While maintaining insulin infusion with low glucose:

  • Monitor potassium closely (every 2-4 hours)—insulin drives potassium intracellularly, and hypokalemia can cause fatal arrhythmias 1, 6
  • Maintain potassium 4-5 mEq/L with aggressive replacement 1
  • Check glucose every 1-2 hours to titrate dextrose infusion 1
  • Monitor pH, bicarbonate, anion gap, and osmolality every 2-4 hours until stable 1

The Evidence Base

The most recent ADA Standards of Care (2024-2025) provide the highest-quality guidance 5, 1. These guidelines emphasize that resolution criteria are metabolic, not glycemic. The 2022 Joint British Diabetes Society guideline 3 specifically addresses the high prevalence of hypoglycemia when insulin is continued, recommending de-escalation to 0.05 units/kg/h when glucose drops below 250 mg/dL (14 mmol/L), but not cessation.

The key principle: insulin's role in DKA/HHS is to shut down ketogenesis and restore cellular glucose uptake—not merely to lower blood glucose. Dextrose infusion allows you to maintain this therapeutic insulin effect while preventing hypoglycemia, ensuring complete metabolic recovery and preventing the high mortality associated with premature treatment discontinuation.

Related Questions

What are the differences in the management of hyperosmolar hyperglycemic state (HHS) and diabetic ketoacidosis (DKA)?
Is bowel rest (nil by mouth) a standard component of management for a hyperglycemic crisis such as diabetic ketoacidosis or hyperosmolar hyperglycemic state?
How should I manage a diabetic patient with an insulin pump who presents with diabetic ketoacidosis or hyperosmolar hyperglycemic state?
What are the current management guidelines for diabetic ketoacidosis in type 1 diabetes and hyperosmolar hyperglycemic state in type 2 diabetes?
Which initial fluid therapy regimen is appropriate for a 72-year-old type 2 diabetic with normal renal function presenting with hyperosmolar coma, severe hyperglycemia, and low‑normal serum potassium?
What are the differences between giving mannitol or hypertonic saline as a bolus versus a continuous infusion for intracranial hypertension?
What are the grades assigned to the recommendations for antenatal corticosteroid use in the late‑preterm period?
What are the possible causes of respiratory distress syndrome in a full-term infant?
Can you help me organize a PowerPoint presentation on schizoaffective disorder and bipolar disorder for psychiatrists?
For which clinical conditions are the following laboratory tests typically ordered: serum or urine osmolality, urine protein‑creatinine ratio, spot urine sodium, 24‑hour urine sodium, and random (spot) urine sodium?
What is the appropriate Augmentin (amoxicillin/clavulanate) dosing regimen for adult community‑acquired pneumonia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.